Andrew Allen, M.D., Ph.D.

Dr. Andrew Allen is a co-founder of Gritstone Oncology and serves as president, chief executive officer and a member of the board of directors. He was a co-founder of Clovis Oncology where he served as executive vice president of clinical and preclinical development and chief medical officer. Prior to that, he was chief medical officer at Pharmion Corporation, which was sold to Celgene Corporation for $2.9 billion following the development of Vidaza™ for the treatment of myelodysplastic syndromes and Thalomid™ for the front-line treatment of multiple myeloma. Previously, Dr. Allen served in clinical development leadership roles at Chiron Corporation and Abbott Laboratories, and worked at McKinsey & Company, where he advised life science companies on strategic issues. He currently serves on the board of directors of Epizyme and Cell Design Labs. Dr. Allen received a medical degree from Oxford University and a Ph.D. in immunology from Imperial College London.

Richard A. Heyman, Ph.D.

Dr. Richard A. Heyman is executive chairman and co-founder of Metacrine, a biotech start-up company developing new therapeutics for the treatment of diabetes and related metabolic disorders. Previously, he served as chief executive officer of Seragon Pharmaceuticals, which was acquired by Genentech/Roche. Prior to Seragon, he co-founded and was chief executive officer of Aragon Pharmaceuticals, which was purchased by Johnson & Johnson. Earlier in his career, Dr. Heyman co-founded and served as chief scientific officer of X-Ceptor Therapeutics and held various roles at Ligand Pharmaceuticals, where he identified and developed Panretin® and Targretin®, retinoids approved by the FDA for the treatment of cancer. He is the author or inventor on more than 120 publications and patents. Dr. Heyman serves on the board of trustees of the Salk Institute for Biological Studies and is a board member of Receptos, Organovo and BIOCOM. He is also a member of the Therapeutic Advisory Board for aTyr Pharma and serves on the Executive Committee of the UCSD Moores Cancer Center. Dr. Heyman received a B.S. in chemistry from the University of Connecticut and a Ph.D. in pharmacology from the University of Minnesota. He was an NIH post-doctoral fellow and staff scientist at the Salk Institute.

Patrick J. Mahaffy, Chairman

Patrick J. Mahaffy is a co-founder of Clovis Oncology and has served as president and chief executive officer and a member of the board of directors since the company’s inception. Previously, he served as president and chief executive officer and as a member of the board of directors at Pharmion Corporation, which he founded and sold to Celgene Corporation. Before that, Mahaffy was president and chief executive officer of NeXagen and its successor, NeXstar Pharmaceuticals. Earlier in his career, Mahaffy was a vice president at the private equity firm E.M. Warburg Pincus and Co. He currently serves on the boards of directors of Orexigen Therapeutics and Flexion Therapeutics and is a trustee of Lewis and Clark College. Mahaffy has a B.A. in international affairs from Lewis and Clark College and an M.A. in international affairs from Columbia University.

Nicholas Simon

Nicholas Simon has been a managing director of Clarus Ventures since the firm’s inception. Prior to Clarus, he was a general partner at MPM Capital, a healthcare venture capital firm. He has more than 20 years of operating and investment experience in the biopharmaceutical industry, including serving as vice president of business and corporate development at Genentech. Simon is currently a member of the board of directors of Nuvelution Pharma and chairman of Sientra. He has been a member of the board of directors of numerous private and public life science companies, including Achillion, Avanir Pharmaceuticals (acquired by Otsuka Pharmaceuticals), Barrier Therapeutics (acquired by Stiefel Laboratories), Biovitrum AB, Cotherix (acquired by Actelion), InterMune (acquired by Roche), Pearl Therapeutics, (acquired by AstraZeneca), Quatrx Pharmaceuticals, Rigel and Sangstat (acquired by Genzyme). Simon is a member of the Foundation Board at the Gladstone Institute, a private not-for-profit research institute affiliated with the University of California, San Francisco. He received a B.S. in microbiology from the University of Maryland and an M.B.A. from Loyola University.

Peter Svennilson

Peter Svennilson is the founder and managing partner of The Column Group (TCG), a San Francisco-based biotech venture firm. He has worked in venture capital and finance for the past 30 years. He was the chairman of Aragon Pharmaceuticals from its inception until it was sold to Johnson & Johnson and was the chairman of Seragon Pharmaceuticals until it was sold to Genentech. Prior to TCG, he was the founder and managing partner of Three Crowns Capital where he helped finance large parts of the venture capital for biotech companies including Tularik, Rosetta, PTC, Chemocentryx, Rinat, Tercica, Somalogic, Infinity and Five Prime. Prior to joining Three Crowns Capital, he was the associate managing director in charge of European Investment Banking Origination at Nomura in London. Svennilson is the chairman of ORIC Pharmaceuticals and a member of the boards of directors of NGM Biopharmaceuticals and Immune Design. He is also a trustee at The Institute for Advanced Study in Princeton, N.J.

Tom Woiwode, Ph.D.

Dr. Tom Woiwode is a managing director at Versant Ventures, where he previously served as a venture partner.  At Versant, he has served in a number of operating roles, most recently as chief operating officer of Okairos, a biopharmaceutical company developing genetic vaccines for major infectious diseases. Dr. Woiwode led the process that culminated in the sale of Okairos to GlaxoSmithKline for $325 million. Prior to his role with Okairos, he co-founded EuroVentures, a wholly owned biotech incubator within Versant Ventures and, in this role, served as the founding chief business officer for three biotech companies created within Versant: Flexion (public), Synosia (public, merged with BioTie), and Amira (acquired by Bristol-Myers Squibb for up to $475 million). Prior to his role as a venture partner at Versant Ventures, he was a principal and served on the boards of Antipodean, Metabolex and Saegis. Before joining Versant, Dr. Woiwode was a research scientist at XenoPort. He currently serves on the boards of directors of Annapurna, Anokion, Audentes, CRISPR, Kanyos Bio and Therachon. He graduated summa cum laude from UC Berkeley with a B.A. in English and received the Departmental Citation for his B.S. in chemistry. He earned a Ph.D. in organic chemistry as an NSF Fellow at Stanford University.